- Company
- Trulicity's share reaches 99.8%
- by Kim, Jin-Gu Aug 28, 2023 05:21am
- Trulicity, a GLP-1 analog class diabetes treatment, once again set the record for highest sales. However, it is unclear whether this upward trend will continue in the second half. This is because it is said that some disruptions have occurred in domestic supply due to a shortage of global distribution supplies. Ozempic and Rybelsus, which ar
- Company
- Discussion on expanding coverage for Leclaza begins
- by Eo, Yun-Ho Aug 28, 2023 05:21am
- Attention is focused on expanding insurance coverage for the first-line treatment of the anticancer drug Leclaza. According to related industries, Yuhan Corporation's 3rd generation EGFR TKI Leclaza will be scheduled for the HIRA on the 30th. The specific indication is 'primary treatment for EGFR active non-small cell lung cancer'. Leclaza o
- Company
- New drug Shingrix leads shingles vaccine mkt
- by Chon, Seung-Hyun Aug 28, 2023 05:21am
- GlaxoSmithKline's shingles vaccine 'Shingrix' took the lead in Korea’s market just 7 months after its release. With its powerful shingles prevention effect, its sales surpassed that of its competitors. SkYZoster, a homegrown vaccine, had taken the lead in the market for the first time at the end of last year but was overtaken by Shingrix in jus
- Company
- Hanmi Pharm starts P1T on its next-gen immuno-oncology drug
- by Chon, Seung-Hyun Aug 25, 2023 06:06am
- On the 22nd, Hanmi Pharm announced that it has recently received approval to initiate a domestic Phase I trial for its next-generation immuno-oncology drug ‘‘BH3120(PD-L1/4-1BB BsAb)’ from the Ministry of Food and Drug Safety. In May, the company had previously received approval from the US FDA for the same drug candidate after submitting an
- Company
- Company Roche and Drug Keytruda will lead industry in 5 yrs
- by Kim, Jin-Gu Aug 25, 2023 06:06am
- A projection has been made that Roche will become the top global-grossing pharmaceutical company 5 years from now in 2028. Evaluate, the global pharmaceutical market analysis institution that released such projections, also predicted that Keytruda would take over Humira’s throne and become the No. 1 grossing drug among pharmaceuticals. On th
- Company
- Will the new NMOSD drug Enspryng be reimbursed in KOR?
- by Eo, Yun-Ho Aug 24, 2023 05:46am
- Whether the new drug for neuromyelitis optica spectrum disorder (NMOSD) can be reimbursed in Kore is gaining attention. Dailypharm found that Roche Korea is carrying out pricing negotiations with the National Health Insurance Service for the reimbursement of its NMOSD treatment Ensprying (satralizumab). The drug passed the Health Insur
- Company
- The report distorted the side effects of JW Pharma Hemlibra
- by Kim, Jin-Gu Aug 23, 2023 05:46am
- Rather, JW Pharma's official position is that the total number of adverse events, including thromboembolism, is more than three times greater in factor VIII. JW Pharma issued a statement on the 22nd and refuted the press release distributed by GC Pharma the previous day (21st). GC Pharma participated in the Bleeding Disorders Conference and d
- Company
- FST measure remains the issue for Luxturna's reimb
- by Eo, Yun-Ho Aug 23, 2023 05:46am
- Whether the differences in opinion over the ‘performance-based standard’ that has risen as an issue during reimbursement discussions for the one-shot retinal dystrophy treatment ‘Luxturna’ will be reconciled is gaining attention. Dailypharm found that the full-field sensitivity threshold (FST) has been set as the standard for evaluati
- Company
- What to do with the loss of drug price cuts?
- by Chon, Seung-Hyun Aug 22, 2023 05:31am
- Pharmaceutical companies are in deep trouble ahead of the end of generic drug price re-evaluation. As each pharmaceutical company announces drug price cuts for as many as 100 or more products, the atmosphere is concentrating on figuring out the size of the loss. Dissatisfaction with the government's indiscriminate re-evaluation of drug price
- Company
- JW Shinyak will resume sales of flu vaccine SKYCellflu
- by Kim, Jin-Gu Aug 22, 2023 05:31am
- On the 21st, JW Shinyak announced that it will resume sales of SK Bioscience’s flu vaccine ‘SKYCellflu Quadrivalent Prefilled Syringe.’ The company signed a joint marketing agreement for ‘SKYCellflu Quadrivalent Prefilled Syringe’ in 2016, and has been responsible for the sales and marketing of the drug at specialized dermatology, ur
